Rescue Therapy Use in Patients with Diabetic Macular Edema (DME) Receiving Intravitreal Aflibercept (IVT-AFL) or Laser: Results from the VIVID-DME and VISTA-DME Trials

被引：0

作者：

Rehak, Matus ^{[1
]}

Korobelnik, Jean-Francois ^{[2
]}

Metzig, Carola ^{[3
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Hop Pellegrin, F-33076 Bordeaux, France

[3] Bayer Healthcare, Berlin, Germany

来源：

OPHTHALMOLOGICA | 2014年 / 232卷

关键词：

Diabetic Macular Edema; Rescue Therapy; Diabetic Retinopathy; Anti-Vascular Endothelial Growth Factor; Aflibercept;

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

147

引用

页码：17 / 18

页数：2

共 46 条

[21] Impact of Systemic Dipeptidyl Peptidase-4(DPP-4) Inhibitors on Treatment Outcomes for Diabetic Macular Edema (DME) in the VISTA and VIVID trials
Rahimy, Ehsan
Baker, Keith
Thompson, Desmond
Saroj, Namrata
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[22] Therapeutic response of patients with Diabetic macular edema (DME) with micropulsed yellow laser 577nm and intravitreal bevacizumab
Rios, Geovanni Jassiel
Rojas, Sergio
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[23] Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: ROTATED Trial 52 Week Results
Taylor, Caitlen
Frazier, Heather
Rex, Priscila
Marcus, William
Starnes, Davis
Walia, Harveen
Singh, Harinderjit
Lalane, Robert
Marcus, Dennis M.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
[24] Primary Results from Two Phase 3 Trials of Faricimab for Diabetic Macular Edema (DME): YOSEMITE and RHINE
Hu, Allen
Willis, Jeffrey R.
Haskova, Zdenka
Silverman, David
Ives, Jane
Basu, Karen
Lin, Hugh
DIABETES, 2021, 70
[25] Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: 6-Month ROTATED Trial Results
Marcus, Dennis M.
Frazier, Heather
Rex, Priscila
Marcus, William
Starnes, Davis
Walia, Harveen
Singh, Harinderjit
Lalane, Robert
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[26] Are Improvements in Diabetic Retinopathy Severity Clinically Meaningful? Insights from Studies of Intravitreal Ranibizumab (RBZ) in Patients with Diabetic Macular Edema (DME)
Ehrlich, Jason S.
Zhang, Jiameng
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
[27] Long-term maintenance of vision required to drive in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) following anti-VEGF intravitreal therapy (IVT)
Emami-Naeini, Parisa
Boucher, Nicholas
Fernando, Rusirini
Menezes, Alicia
Garmo, Vincent
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
[28] Open-Label Phase 2 Study of Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema (DME) in Vitrectomized Patients: Interim Results
Gupta, S.
Boyer, D. S.
Faber, D.
Patel, S. S.
Liu, C. -C.
Li, X. -Y.
Whitcup, S. M.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
[29] Effect of Baseline Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) on Treatment Outcomes With Intravitreal Aflibercept Injection (IAI) or Macular Laser Photocoagulation in Diabetic Macular Edema (DME)
Ogura, Yuichiro
Feltgen, Nicolas
Korobelnik, Jean-Francois
Midena, Edoardo
Katz, Todd A.
Teukmantel, Claudia
Metzig, Carola
Zeitz, Oliver
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
[30] TREATMENT PATTERNS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND LASER THERAPY AMONG PATIENTS WITH DIABETIC MACULAR EDEMA (DME)
Jiang, S.
Barner, J. C.
Park, C.
Ling, Y. L.
VALUE IN HEALTH, 2014, 17 (03) : A260 - A260

← 1 2 3 4 5 →